Jill Bryant
Family · Williamsburg, KYNPI 1568778256
Payments from drug & device makers
Across 90 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$519
- Indivior Inc.$306
- Amgen$142
- Abbott$61
- Gilead$56
- Axsome Therapeutics, Inc.$50
- plus $239 from 12 others
What the payments were for
- Food & beverage$1,373100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $519 |
| Indivior Inc. | 20 | $306 |
| Amgen | 6 | $142 |
| Abbott | 4 | $61 |
| Gilead | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Braeburn Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Medtronic | 1 | $26 |
| Novo Nordisk | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| GSK | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$1,373 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $71,382 |
| OzempicSemaglutide | 40 | $36,884 |
| EliquisApixaban | 57 | $34,627 |
| JanuviaSitagliptin Phosphate | 36 | $25,678 |
| TrulicityDulaglutide | 27 | $24,786 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 183 | $13,670 |
| FarxigaDapagliflozin Propanediol | 15 | $12,580 |
| JardianceEmpagliflozin | 14 | $9,607 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,380 |
| Repatha SyringeEvolocumab | 15 | $7,991 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,284 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,006 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $3,443 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $3,312 |
| Ventolin HfaAlbuterol Sulfate | 57 | $3,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $17 | $96,16891 claims |
| Novo NordiskOzempic | $20 | $36,88440 claims |
| MerckJanuvia | $11 | $25,67836 claims |
| AstraZenecaFarxiga, Symbicort | $17 | $16,58633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.
Other family in Williamsburg
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.